Evidence map›Paper›PMID 40418512›Full record

ArticleBreast cancer (Tokyo, Japan)2025

Immediate breast reconstruction surgery for breast cancer: current status and future directions.

Tadahiko Shien, Hiroko Nogi, Akiko Ogiya, Makoto Ishitobi, Chikako Yamauchi, Ayaka Shimo, Kazutaka Narui, Naomi Nagura, Hirohito Seki, Kaori Terata and 7 more

Abstract read
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tadahiko ShienDepartment of Breast and Endocrine Surgery, Okayama University Hospital, 2-5-1 Shikata-Cho, Kita-Ku, Okayama, 7008558, Japan. tshien@md.okayama-u.ac.jp.ORCID http://orcid.org/0000-0003-3202-5512
Hiroko NogiDepartment of Breast and Endocrine Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Akiko OgiyaDepartment of Breast Surgery, Japanese Red Cross Medical Center, Tokyo, Japan.
Makoto IshitobiDepartment of Breast Surgery, Mie University School of Medicine, Mie, Japan.
Chikako YamauchiDepartment of Radiation Oncology, Shiga General Hospital, Shiga, Japan.
Ayaka ShimoDepartment of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kanagawa, Japan.
Kazutaka NaruiDepartment of Breast and Thyroid Surgery, Medical Center, Yokohama City University, Kanagawa, Japan.
Naomi NaguraDepartment of Breast Surgical Oncology, St Luke's International Hospital, Tokyo, Japan.
Hirohito SekiDepartment of Breast Surgery, Kyorin University School of Medicine, Tokyo, Japan.
Kaori TerataDepartment of Breast and Endocrine Surgery, Akita University Hospital, Akita, Japan.
Miho SaigaDepartment of Plastic Surgery, Okayama University Hospital, Okayama, Japan.
Tatsuya UchidaDepartment of Plastic Surgery, Okayama University Hospital, Okayama, Japan.
Shinsuke SasadaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Teruhisa SakuraiSakurai Breast Clinic, Wakayama, Japan.
Naoki NiikuraDepartment of Breast Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Hiroki MoriDepartment of Plastic and Reconstructive Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Japanese Breast Cancer Society’s Collaborative Study Group of Scientific Research

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmediate breast reconstruction (IBR) has become increasingly recognized in Japan as an important component of breast cancer care, improving patients' quality of life after mastectomy. While the adoption of IBR is growing, the reconstruction rate in Japan remains lower than in Western countries. To clarify the current practice and challenges, the Japanese Breast Cancer Society (JBCS) conducted a nationwide survey.

methodsWe conducted a comprehensive web-based questionnaire survey among all JBCS-certified institutions between December 2020 and February 2021. The survey assessed institutional capabilities, surgical techniques, decision-making criteria for BR, and the integration of adjuvant therapy.

resultsA total of 429 institutions responded, with 72.5% offering BR and 61.7% capable of providing immediate reconstruction. Nipple-sparing mastectomy (NSM) was performed at 73.7% of institutions offering reconstruction. Multidisciplinary conferences with plastic surgeons were held at 70.5% of institutions. Approximately 30% of institutions discontinued IBR if sentinel lymph node metastases were detected intraoperatively, and 62.8% avoided recommending IBR for patients likely to require postoperative radiation therapy. In 94% of institutions, BR did not cause delays in the administration of adjuvant chemotherapy. However, 15% of institutions modified their radiation therapy approach in reconstructed patients. Additionally, 27% of physicians still believed that BR could negatively affect prognosis.

conclusionsThe survey confirmed that IBR is widely performed and feasible in Japan. However, institutional differences, limited access to plastic surgeons, and persistent misconceptions remain significant barriers. Strengthening multidisciplinary collaboration and establishing standardized guidelines will help improve BR rates and patient outcomes in Japan.

Indexed as

Breast NeoplasmsMammaplastyChemotherapy, AdjuvantFemaleHumansJapanMastectomyQuality of LifeRadiotherapy, AdjuvantSurveys and QuestionnairesBreast cancerComplicationsImmediate reconstruction surgeryPrognosis

Identifiers

PMID40418512
PMCPMC12174185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.